Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sham S. Nikam"'
Autor:
Sham S. Nikam, Russell J. DeOrazio, David D. Manning, Scott Ian L, Brian Alan Sherer, Jun-Ho Maeng
Publikováno v:
Synthetic Communications. 41:3551-3555
The double metallation of 6-bromo-3H-benzothiazol-2-one and 6-bromo-3H-benzoxazol-2-one with methyl magnesium bromide and alkyllithium bases is described. Alkylation with a variety of electrophiles occurs at the 6-position of the heterocycles in good
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:489-493
As part of an on-going effort to investigate the chemical space requirements for D(2)/5-HT(2A) receptor antagonists as atypical antipsychotics, new 1-aminoindanes were synthesized. The replacement of the heterocycle (oxindole) in ziprasidone with a c
Autor:
David L. Rock, Sham S. Nikam, Joel Murray, Abdul Mutlib, Hao Chen, Lloyd Dethloff, Brian Edward Kornberg
Publikováno v:
Chemical Research in Toxicology. 19:1341-1350
Compound 1a (6-chloro-5-{3-[4-(1H-indazol-3-yl)-piperazin-1-yl]-propyl}-3,3-dimethyl-1,3-dihydro-indol-2-one) was mutagenic to Salmonella typhimurium TA98 in the presence of rat liver S9 subcellular fraction. The metabolism of 1a in rat liver S9 or m
Autor:
Kyunghye Ahn, Semiko Kaw, Richard L Schroeder, Sharon Pan, Sarah B. Herman, Masashi Yanagisawa, Stephen J. Haleen, Donald Hupe, Noriaki Emoto, Sham S. Nikam, Xue Min Cheng, Andre M. Sisneros, Lee Chitase, Annette M. Doherty
Publikováno v:
Biochemical and Biophysical Research Communications. 243:184-190
PD 069185 is a highly selective and structurally novel inhibitor of endothelin converting enzyme-1 (ECE-1). PD 069185 is a trisubstituted quinazoline with an IC50 value of 0.9 +/- 0.1 microns for inhibition of human ECE-1 from the solubilized membran
Autor:
Zhiping Li, Chao-Jun Li, Timothy E. Wilson, Michael P. Doyle, Maxim O. Ratnikov, Patricia D. MacLeodé, Andrew K. Jones, Sham S. Nikam
Publikováno v:
e-EROS Encyclopedia of Reagents for Organic Synthesis
[75-91-2] C4H10O2 (MW 90.12) InChI = 1S/C4H10O2/c1-4(2,3)6-5/h5H,1-3H3 InChIKey = CIHOLLKRGTVIJN-UHFFFAOYSA-N (oxidizing agent used for the oxidation of alcohols and alkenes to allylic oxygenated compounds and epoxides1, 2) Alternate Name: TBHP. Phys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f32ba9a3c37e59098d642aedbaf79d
https://doi.org/10.1002/047084289x.rb385.pub3
https://doi.org/10.1002/047084289x.rb385.pub3
Autor:
Russell J. DeOrazio, Scott Ian L, David D. Manning, Jun-Ho Maeng, Brian Alan Sherer, Sham S. Nikam
Publikováno v:
ChemInform. 43
The double metallation of 6-bromo-3H-benzothiazol-2-one and 6-bromo-3H-benzoxazol-2-one with methyl magnesium bromide and alkyllithium bases is described. Alkylation with a variety of electrophiles occurs at the 6-position of the heterocycles in good
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 9(1)
There is growing pressure to find more effective therapies for major psychiatric disorders, such as schizophrenia and depressive disorder. The repeated disappointments that have been experienced with highly selective, single-target agents have prompt
Autor:
Sham S, Nikam, Alok K, Awasthi
Publikováno v:
Current opinion in investigational drugs (London, England : 2000). 9(1)
Many of the drugs currently marketed for the treatment of schizophrenia are dopamine D2 receptor antagonists or partial agonists with or without mixed receptor pharmacology, and primarily treat the positive symptoms of schizophrenia. These drugs, dep
Autor:
Leonard T. Meltzer, Sham S. Nikam, Jon L. Wright, Julie McCormick, Kevin A. Serpa, Brian Edward Kornberg, Bridget M. Barr, Suzanne Ross Kesten, Linda L. Coughenour
Publikováno v:
ChemInform. 35
A benzylpiperidine analogue with an acetylenic linker, 5-(3-[4-(4-fluorobenzyl)-piperidin-1-yl]-prop-1-ynyl)-1,3-dihydrobenzimidazol-2-one (3), was identified as a chemical lead with excellent activity at the NR1A/2B receptor (IC50=3 nM). Efforts to
Autor:
Leonard T. Meltzer, Sham S. Nikam
Publikováno v:
Current pharmaceutical design. 8(10)
NR2B antagonists have received considerable attention in recent years. In this class of excitatory amino acid receptor antagonists NR2B antagonists have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. Several gr